Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
Latest Information Update: 21 Aug 2023
At a glance
- Drugs Iruplinalkib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 21 Aug 2023 New trial record